Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1

Selective sodium–glucose cotransporter 2 (SGLT2) inhibitors reduced the risk of hospitalization for heart failure in patients with or without type 2 diabetes (T2DM) in large-scale clinical trials. The exact mechanism of action is currently unclear. The dual SGLT1/2 inhibitor sotagliflozin not only r...

Descripción completa

Detalles Bibliográficos
Autores principales: Sayour, Alex Ali, Ruppert, Mihály, Oláh, Attila, Benke, Kálmán, Barta, Bálint András, Zsáry, Eszter, Merkely, Béla, Radovits, Tamás
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468664/
https://www.ncbi.nlm.nih.gov/pubmed/34576016
http://dx.doi.org/10.3390/ijms22189852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468664/
https://www.ncbi.nlm.nih.gov/pubmed/34576016
http://dx.doi.org/10.3390/ijms22189852

Ejemplares similares